This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelderblom, H. Articles by Sparreboom, A. Search for Related Content PubMed PubMed Citation Articles by Gelderblom, H. Articles by Sparreboom, A.

Influence of Cremophor EL on the Bioavailability of Intraperitoneal Paclitaxel¹

Departments of Medical Oncology [H. G., J. V., D. M. v. Z., L. O., K. N., G. S., A. S.] and Nuclear Medicine [D. B.], Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, 3075 EA Rotterdam, the Netherlands

It has been hypothesized that the paclitaxel vehicle Cremophor EL (CrEL) is responsible for nonlinear drug disposition by micellar entrapment. To gain further insight into the role of CrEL in taxane pharmacology, we studied the pharmacokinetics of paclitaxel in the presence and absence of CrEL after i.p. and i.v. dosing. Patients received an i.p. tracer dose of [G-³H]paclitaxel in ethanol without CrEL (100 µCi diluted further in isotonic saline) on day 1, i.p. paclitaxel formulated in CrEL (Taxol; 125 mg/m²) on day 4, an i.v. tracer of [G-³H]paclitaxel on day 22, and i.v. Taxol (175 mg/m²) on day 24. Four patients (age range, 54–74 years) were studied, and serial plasma samples up to 72 h were obtained and analyzed for total radioactivity, paclitaxel, and CrEL. In the presence of CrEL, i.v. paclitaxel clearance was 10.2 ± 3.76 liters/h/m² (mean ± SD), consistent with previous findings. The terminal disposition half-life was substantially prolonged after i.p. dosing (17.0 ± 11.3 versus 28.7 ± 8.72 h), as was the mean residence time (7.28 ± 2.76 versus 40.7 ± 13.8 h). The bioavailability of paclitaxel was 31.4 ± 5.18%, indicating insignificant systemic concentrations after i.p. treatment. CrEL levels were undetectable after i.p. dosing (<0.05 µl/ml), whereas after i.v. dosing, the mean clearance was 159 ± 58.4 ml/h/m², in line with earlier observations. In the absence of CrEL, the bioavailability and systemic concentrations of i.p. paclitaxel were significantly increased. This finding is consistent with the postulated concept that CrEL is largely responsible for the pharmacokinetic advantage for peritoneal cavity exposure to total paclitaxel compared with systemic delivery.

This article has been cited by other articles:

				E. deBree, H. Rosing, D. Filis, J. Romanos, M. Melisssourgaki, M. Daskalakis, M. Pilatou, E. Sanidas, P. Taflampas, K. Kalbakis, et al. Cytoreductive Surgery and Intraoperative Hyperthermic Intraperitoneal Chemotherapy with Paclitaxel: A Clinical and Pharmacokinetic Study Ann. Surg. Oncol., April 1, 2008; 15(4): 1183 - 1192. [Abstract] [Full Text] [PDF]

				A. H. Kyle, L. A. Huxham, D. M. Yeoman, and A. I. Minchinton Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors Clin. Cancer Res., May 1, 2007; 13(9): 2804 - 2810. [Abstract] [Full Text] [PDF]

				S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338. [Abstract] [Full Text] [PDF]

				A. Sparreboom, C. D. Scripture, V. Trieu, P. J. Williams, T. De, A. Yang, B. Beals, W. D. Figg, M. Hawkins, and N. Desai Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) Clin. Cancer Res., June 1, 2005; 11(11): 4136 - 4143. [Abstract] [Full Text] [PDF]